Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC blinatumomab in pediatric relapsed/refractory and MRD-positive B-ALL (Phase 1b/2, Japan)
jRCT2031250508Phase 2Suspended
- Sponsor
- Amgen
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Amgen. Primary endpoints: Phase 1b: Dose-limiting toxicities, Phase 1b: Treatment-emergent adverse events and 5 more. Started Dec 2025; status: suspended.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031250508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250508.